CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics
CTMX Stock Summary
- The price/operating cash flow metric for CytomX Therapeutics Inc is higher than 95.22% of stocks in our set with a positive cash flow.
- Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 12.25% of US stocks have a lower such ratio.
- As for revenue growth, note that CTMX's revenue has grown 74.58% over the past 12 months; that beats the revenue growth of 93.08% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CytomX Therapeutics Inc are MTEM, VYGR, FIXX, CRBP, and NTLA.
- Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.
CTMX Stock Price Chart Interactive Chart >
CTMX Price/Volume Stats
| Current price | $9.09 | 52-week high | $15.44 |
| Prev. close | $8.96 | 52-week low | $6.25 |
| Day low | $8.64 | Volume | 686,774 |
| Day high | $9.25 | Avg. volume | 1,001,830 |
| 50-day MA | $8.10 | Dividend yield | N/A |
| 200-day MA | $7.49 | Market Cap | 588.89M |
CytomX Therapeutics, Inc. (CTMX) Company Bio
CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.
Latest CTMX News From Around the Web
Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
JPMorgan: 2 Stocks for Stellar Long-Term GainsAccording to JPMorgan CEO Jamie Dimon, the US is on the cusp of an economic boom which should fuel growth at least until 2023. Dimon attributes the prospect of strong growth to several reasons. “I have little doubt that with excess savings, new stimulus savings, huge deficit spending, more QE, a new potential infrastructure bill, a successful vaccine and euphoria around the end of the pandemic, the U.S. economy will likely boom,” Dimon recently said. |
CytomX Therapeutics Announces New Employment Inducement GrantsSOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that on April 1, 2021, the Company granted a new employee an option to purchase a total of 120,000 shares of the Company’s common stock at an exercise price per share equal to $7.87, which was the closing trading price on April 1, 2021, the date of the grant. In addition, on April 12, 2021, the Company also granted another new employee an option to purchase a total of 275,000 shares of the Company’s common stock at an exercise price per share equal to $6.74, which was the clos... |
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that it will host a virtual investor event at 1:00 p.m. – 3:00 p.m. ET / 10:00 a.m. – 12:00 p.m. PT on Wednesday, April 7, 2021. In addition to company executives, CytomX’s investor event will feature presentations from and an interactive Q&A session with industry experts, including: John Lambert Ph.D., Queen’s University Belfast, an expert on conditionally activated antibody-drug conjugates (ADCs),Sara M. Tolaney, M.D., Dana-Farber Cancer Institute, Harvard Medical School, an... |
CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Moving Average Crossover Alert: CytomX Therapeutics (CTMX)CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. |
CTMX Price Returns
| 1-mo | 14.77% |
| 3-mo | 36.69% |
| 6-mo | 34.47% |
| 1-year | -1.52% |
| 3-year | -65.15% |
| 5-year | -32.52% |
| YTD | 38.78% |
| 2020 | -21.18% |
| 2019 | -44.97% |
| 2018 | -28.47% |
| 2017 | 92.08% |
| 2016 | -47.34% |
Continue Researching CTMX
Want to do more research on CytomX Therapeutics Inc's stock and its price? Try the links below:CytomX Therapeutics Inc (CTMX) Stock Price | Nasdaq
CytomX Therapeutics Inc (CTMX) Stock Quote, History and News - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...